

Katrien Van Bocxlaer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1717037/publications.pdf>

Version: 2024-02-01

17
papers

512
citations

687363

13
h-index

888059

17
g-index

18
all docs

18
docs citations

18
times ranked

746
citing authors

#	ARTICLE	IF	CITATIONS
1	Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2019, 11, 106-117.	3.4	58
2	Leishmaniasis immunopathologyâ€™ impact on design and use of vaccines, diagnostics and drugs. <i>Seminars in Immunopathology</i> , 2020, 42, 247-264.	6.1	51
3	Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2019, 11, 129-138.	3.4	44
4	Drug permeation and barrier damage in <i>Leishmania</i> -infected mouse skin. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1578-1585.	3.0	42
5	Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse model. <i>Journal of Pharmacy and Pharmacology</i> , 2016, 68, 862-872.	2.4	39
6	Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations FungisomeÂ® and AmBisomeÂ® in murine cutaneous leishmaniasis. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2018, 8, 223-228.	3.4	37
7	Activity of Amphotericin B-Loaded Chitosan Nanoparticles against Experimental Cutaneous Leishmaniasis. <i>Molecules</i> , 2020, 25, 4002.	3.8	35
8	Topical Treatment for Cutaneous Leishmaniasis: Dermato-Pharmacokinetic Lead Optimization of Benzoxaboroles. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	29
9	Relation between Skin Pharmacokinetics and Efficacy in AmBisome Treatment of Murine Cutaneous Leishmaniasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	28
10	Characterization of a new <i>Leishmania</i> major strain for use in a controlled human infection model. <i>Nature Communications</i> , 2021, 12, 215.	12.8	28
11	Efficacy of Paromomycin-Chloroquine Combination Therapy in Experimental Cutaneous Leishmaniasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	27
12	Pharmacokinetics and Pharmacodynamics of the Nitroimidazole DNDI-0690 in Mouse Models of Cutaneous Leishmaniasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	25
13	Local Skin Inflammation in Cutaneous Leishmaniasis as a Source of Variable Pharmacokinetics and Therapeutic Efficacy of Liposomal Amphotericin B. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	23
14	Tackling Drug Resistance and Other Causes of Treatment Failure in Leishmaniasis. <i>Frontiers in Tropical Diseases</i> , 2022, 3, .	1.4	17
15	A single dose of antibody-drug conjugate cures a stage 1 model of African trypanosomiasis. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007373.	3.0	11
16	Film-Forming Systems for the Delivery of DNDI-0690 to Treat Cutaneous Leishmaniasis. <i>Pharmaceutics</i> , 2021, 13, 516.	4.5	11
17	Pharmacokinetics and pharmacodynamics in the treatment of cutaneous leishmaniasis â€™ challenges and opportunities. <i>RSC Medicinal Chemistry</i> , 2021, 12, 472-482.	3.9	7